Found: 13
Select item for more details and to access through your institution.
Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 5, p. 374, doi. 10.1002/cpdd.255
- By:
- Publication type:
- Article
A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 5, p. 383, doi. 10.1002/cpdd.260
- By:
- Publication type:
- Article
Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 12, p. 1394, doi. 10.1002/cpdd.1178
- By:
- Publication type:
- Article
Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
- Published in:
- Journal of Diabetes Investigation, 2017, v. 8, n. 1, p. 84, doi. 10.1111/jdi.12538
- By:
- Publication type:
- Article
A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers.
- Published in:
- Biotechnology & Bioengineering, 2009, v. 103, n. 1, p. 187, doi. 10.1002/bit.22219
- By:
- Publication type:
- Article
Pharmacokinetic–pharmacodynamic (dipeptidyl peptidase‐4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once‐weekly administered omarigliptin.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 12, p. 2759, doi. 10.1111/bcp.14103
- By:
- Publication type:
- Article
A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 2, p. 403, doi. 10.1002/cpt.1998
- By:
- Publication type:
- Article
Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 104, n. 5, p. 865, doi. 10.1002/cpt.1183
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 12, p. 1528, doi. 10.1002/jcph.773
- By:
- Publication type:
- Article
Placebo- and Amitriptyline-Controlled Evaluation of Central Nervous System Effects of the NK<sub>1</sub> Receptor Antagonist Aprepitant and Intravenous Alcohol Infusion at Pseudo-Steady State.
- Published in:
- Journal of Clinical Pharmacology, 2013, v. 53, n. 8, p. 846, doi. 10.1002/jcph.120
- By:
- Publication type:
- Article
A randomized clinical trial to evaluate the single‐dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes.
- Published in:
- Pediatric Diabetes, 2019, v. 20, n. 1, p. 48, doi. 10.1111/pedi.12790
- By:
- Publication type:
- Article
Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin.
- Published in:
- Diabetes Therapy, 2013, v. 4, n. 2, p. 431, doi. 10.1007/s13300-013-0045-8
- By:
- Publication type:
- Article
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 2, p. 177, doi. 10.1177/13524585231216854
- By:
- Publication type:
- Article